Neetika Khurana

Neetika Khurana

Auto-generated profile, based on publicly available information

Neetika Khurana

Department of Cancer Biology, Loyola University Chicago, Maywood, Illinois. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2024 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
RKRaymond Kostlan
Raymond Kostlan
JPJohn T. Phoenix
John T. Phoenix
ABAudris Budreika
Audris Budreika
MFMarina G. Ferrari
Marina G. Ferrari
NKNeetika Khurana
Neetika Khurana
SKSteven Kregel
Steven Kregel
There is tremendous need for improved prostate cancer models. Anatomically and developmentally, the mouse prostate differs from the human prostate and does not form tumors spontaneously. Genetically engineered mouse models lack the heterogeneity of human cancer and rarely establish metastatic growth. Human xenografts are an alternative but must rely on an immunocompromised host. Therefore, we generated prostate cancer murine xenograft models with an intact human immune system (huNOG and huNOG-EXL mice) to test whether humanizing tumor-immune interactions would improve modeling of metastatic prostate cancer and the impact of androgen receptor-targeted and immunotherapies. These mice maintain multiple human immune cell lineages, including functional human T-cells and myeloid cells. Implications: To the best of our knowledge, results illustrate the first model of human prostate cancer that has an intact human immune system, metastasizes to clinically relevant locations, responds appropriately to standard-of-care hormonal therapies, and can model both an immunosuppressive and checkpoint-inhibition responsive immune microenvironment.

17 June 2026
Verified
Other
Open access
RKRaymond Kostlan
Raymond Kostlan
JPJohn T. Phoenix
John T. Phoenix
ABAudris Budreika
Audris Budreika
MFMarina G. Ferrari
Marina G. Ferrari
NKNeetika Khurana
Neetika Khurana
SKSteven Kregel
Steven Kregel
Metastasis by 22Rv1 to the spleen in huNOG and huNOG-EXL mice.

17 June 2026
Verified
Other
Open access
RKRaymond Kostlan
Raymond Kostlan
JPJohn T. Phoenix
John T. Phoenix
ABAudris Budreika
Audris Budreika
MFMarina G. Ferrari
Marina G. Ferrari
NKNeetika Khurana
Neetika Khurana
SKSteven Kregel
Steven Kregel
Metastasis by 22Rv1 to the skull in huNOG and huNOG-EXL mice.

17 June 2026
Verified
Other
Open access
PDF file
RKRaymond Kostlan
Raymond Kostlan
JPJohn T. Phoenix
John T. Phoenix
ABAudris Budreika
Audris Budreika
MFMarina G. Ferrari
Marina G. Ferrari
NKNeetika Khurana
Neetika Khurana
SKSteven Kregel
Steven Kregel
Metastasis by 22Rv1 to the lung in huNOG and huNOG-EXL mice.

4 September 2024
Verified
Other
Open access
PDF file
RKRaymond Kostlan
Raymond Kostlan
JPJohn T. Phoenix
John T. Phoenix
ABAudris Budreika
Audris Budreika
MFMarina G. Ferrari
Marina G. Ferrari
NKNeetika Khurana
Neetika Khurana
SKSteven Kregel
Steven Kregel
Metastasis by 22Rv1 to the skull in huNOG and huNOG-EXL mice.

4 September 2024
Verified
Other
Open access
RKRaymond Kostlan
Raymond Kostlan
JPJohn T. Phoenix
John T. Phoenix
ABAudris Budreika
Audris Budreika
MFMarina G. Ferrari
Marina G. Ferrari
NKNeetika Khurana
Neetika Khurana
SKSteven Kregel
Steven Kregel
Myeloid-support exhibits immuno-dampened profile in huNOG-EXL 22Rv1 xenograft tumors. A, Gating strategy used to determine presence of human CD45+ cells in the NOG-EXL model. B, Representative data showing the abundance of various immune cell populations; human leukocytes, CD19+ cells, CD3+ cells, and double negative cells; MDSC and activated myeloid cells; and helper T cells (CD4+) and cytotoxic T cells (CD8+; top to bottom). C, Quantitated data comparing human CD45, CD3, CD4, and CD11b populations in tumors isolated from testosterone-implanted vehicle, intact vehicle, castrated vehicle, and castrated enzalutamide treated mice. D, Gating strategy for determining the activation state of MDSCs (CD3− CD19− CD11b+ CD14−). E, Representative data showing the activation state of the MDSC cells harvested from tumors under different treatment categories through the presence of the surface markers: CD25, CD44, CD69, and PD-1. F, Quantitated data showing the activation state of the MDSCs throughout the different treatments.